Efficacy and safety of Omalizumab in the treatment of Chronic Urticarial; a case series.

Authors

  • Asif Kamal Islamabad Medical Complex, NESCOM
  • Maryum Nouman Islamabad Medical Complex, NESCOM

DOI:

https://doi.org/10.66344/jpad.27.3.2017.1058

Keywords:

Omalizumab, Urticaria, IgE.

Abstract

Chronic Idiopathic Urticaria (CIU) is a disease with significant impact on the quality of life owing to its morbidity and relative prevalence. Omalizumab is a recombinant monoclonal antibody against IgE that inhibits the binding of IgE to FcεRI on the cell surface. Its role has been thoroughly studied in asthma.We present case series focusing on the role of subcutaneous Omalizumab in the treatment of CIU along with its safety profile by taking into account the immediate and late side effects.

Author Biographies

Asif Kamal, Islamabad Medical Complex, NESCOM

Head of department of Dermatology

Maryum Nouman, Islamabad Medical Complex, NESCOM

Postgraduate Trainee (Medicine/Dermatology)

References

References:

Greaves MW. Chronic urticaria. N Engl J Med 1995;332:1767-1772[Erratum, N Engl J Med 1995;333:1091.]

Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol 2008;20:709-716

Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993 Sep 1;151(5):2623–32.

Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 2):S6–11.

Owen CE. Anti-immunoglobulin E therapy for asthma. Pulm Pharmacol Ther. 2002;15(5):417–24.

Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol. 2000 Feb;18(2):157–62.

MacGlashan DW, Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997 Feb 1;158(3):1438–45.

Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004 Sep;114(3):527–30.

Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003 Dec;112(6):1147–54.

Skin Therapy Letter. 2014;19(6)

Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, Spector S, Maurer M: A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567–573.e1.

Marcus Maurer, M.D., Karin Rosén, M.D., Ph.D., Hsin-Ju Hsieh, Ph.D., Sarbjit Saini, M.D., Clive Grattan, M.D., Ana Gimenéz-Arnau, M.D., Ph.D., Sunil Agarwal, M.D., Ramona Doyle, M.D., Janice Canvin, M.D., Allen Kaplan, M.D., and Thomas Casale, M.D. N Engl J Med 2013; 368:924-935March 7, 2013DOI: 10.1056/NEJMoa1215372

Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567-573

Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128(1):202.e5-209.e5.

Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria, N Engl J Med 2013; 368:924-935March 7, 2013

Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study. The Journal of Investigative Dermatology. 2015;135(1):67-75. doi:10.1038/jid.2014.306.

Downloads

Published

2018-03-15

How to Cite

1.
Kamal A, Nouman M. Efficacy and safety of Omalizumab in the treatment of Chronic Urticarial; a case series. J Pak Assoc Dermatol [Internet]. 2018Mar.15 [cited 2026May2];27(3):282-5. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/1058

Issue

Vol. 27 No. 3 (2017): July - September

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.